Skip to main content

Table 2 The Characteristics of amikacin dose and duration in patients on MDR-TB treatment

From: Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss

  Hearing loss by type of diagnosis
  No hearing loss Hearing loss confirmed by audiogram Clinical diagnosis of hearing loss
Total patients, n (%) 167 (38.2%) 147 (33.6%) 123 (28.2%)
Baseline (initial amikacin dose) dose/kg(kilogram) 17.0 (9.3 – 22.9) 17.2 (15.4 – 18.9) 17.2 (15.3 – 18.8)
Mean daily dose of amikacin (dose/kg/month) 16.2 (14.1 – 18.3) 16.7 (15.3 – 18.9) 16.6 (14.9 – 18.8)
Number of patients in whom amikacin administration was changed from daily to 3 times per week 51 (30.5%) 131 (89.2%) 115 (93.5%)
Mean duration of daily amikacin treatment (days) 164 (2 – 429) 167 (105 – 210) 175 (126 – 213)
Mean duration of amikacin treatment given 3 times per week (days) 67 (2 – 336) 64 (41 – 105) 68 (42 – 108)
Overall duration of amikacin treatment (regardless of censoring; days) 189 (2 – 528) 195 (161 – 243) 200 (175 – 249)
Duration of amikacin treatment before censoring (days) 189 (42 – 632) 170 (104 – 212) 167 (108 – 214)